Bruker Co. (NASDAQ:BRKR) Given Average Rating of “Moderate Buy” by Brokerages

Bruker Co. (NASDAQ:BRKR) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $81.40.

Several research firms have recently issued reports on BRKR. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. The Goldman Sachs Group lowered their price objective on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. TD Cowen lowered their price objective on Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research report on Wednesday, August 7th. Citigroup lowered their price objective on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th. Finally, Wells Fargo & Company began coverage on Bruker in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 target price for the company.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $64.54 on Monday. The stock’s 50-day moving average is $65.12 and its two-hundred day moving average is $69.93. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. Bruker has a 1-year low of $53.79 and a 1-year high of $94.86. The company has a market cap of $9.38 billion, a price-to-earnings ratio of 23.47, a price-to-earnings-growth ratio of 2.52 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, hitting the consensus estimate of $0.52. The company had revenue of $800.70 million for the quarter, compared to the consensus estimate of $799.44 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. Bruker’s revenue was up 17.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.50 EPS. Analysts forecast that Bruker will post 2.61 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Shareholders of record on Monday, September 2nd were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Friday, August 30th. This represents a $0.20 dividend on an annualized basis and a yield of 0.31%. Bruker’s payout ratio is 7.27%.

Institutional Trading of Bruker

Hedge funds have recently added to or reduced their stakes in the stock. TD Asset Management Inc lifted its position in Bruker by 7.4% during the 1st quarter. TD Asset Management Inc now owns 1,788,763 shares of the medical research company’s stock worth $168,036,000 after acquiring an additional 123,984 shares during the period. Nomura Holdings Inc. acquired a new stake in Bruker during the 4th quarter worth approximately $5,593,000. Congress Wealth Management LLC DE lifted its position in Bruker by 21.8% during the 1st quarter. Congress Wealth Management LLC DE now owns 162,191 shares of the medical research company’s stock worth $15,236,000 after acquiring an additional 29,029 shares during the period. Atria Investments Inc acquired a new stake in Bruker during the 1st quarter worth approximately $1,142,000. Finally, Point72 Asset Management L.P. acquired a new stake in Bruker during the 2nd quarter worth approximately $36,472,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.